The stock gave multibagger returns of 450 per cent in just 1 year and a whopping 1,000 per cent in 3 years. 

FII stake increase: Foreign Institutional Investors (FIIs) have increased their stake in Lincoln Pharma from 0.63 per cent in September 2022 to 2.59 per cent in September 2023.

Promoter holding increase: The promoter holding in Lincoln Pharma has also increased from 44.09 per cent in September 2022 to 50.53 per cent in September 2023.

In the previous financial year 2022-2023, the company had declared bonus shares in the ratio 4:1 and stock split from a face value of Rs 5 to a face value of Rs 1. The stock split record date was August 28, 2022 and the bonus shares record date was January 06, 2023.

In Q4FY23, the company witnessed a remarkable surge in net sales, soaring by 1,345 per cent to Rs 33.98 crore, and net profit experienced an astonishing growth of 2,414 per cent, reaching Rs 1.92 crore compared to Q4FY22. Similarly, for the entire FY23, net sales rose by 918 per cent to Rs 506.62 crore, and net profit skyrocketed by 1,047 per cent to Rs 2.01 crore compared to FY22.

The stock delivered a multibagger return of 135.38 per cent in just six months, while the BSE Sensex gained only 17.84 per cent.

Indices witnessed selling pressure towards the end as Nifty closed above the 17,800 level. The benchmark index jumped 1.10 per cent while BSE Sensex climbed 578 points.

Indices ended higher after a volatile second half as Nifty rose 36 points or 0.21 per cent while Sensex jumped nearly 60 points. Nifty Midcap and Nifty Smallcap climbed 0.70 per cent & 0.55 per cent, respectively.  

Indices were on a free fall in the last half an hour as Nifty collapsed over 200 points to close at 17,505.